Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $20.40

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been assigned a consensus rating of “Hold” from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $20.40.

KROS has been the topic of several research reports. Weiss Ratings downgraded shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KROS. Financial Management Professionals Inc. acquired a new position in shares of Keros Therapeutics in the fourth quarter valued at about $29,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after acquiring an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Keros Therapeutics in the third quarter valued at about $103,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Keros Therapeutics in the first quarter valued at about $129,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Price Performance

Shares of KROS opened at $11.25 on Wednesday. The firm has a market capitalization of $222.64 million, a PE ratio of -3.74 and a beta of 0.94. The company’s 50-day moving average is $11.38 and its 200-day moving average is $15.39. Keros Therapeutics has a fifty-two week low of $9.79 and a fifty-two week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The company had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. Analysts predict that Keros Therapeutics will post -5.62 earnings per share for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.